secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2025-01-06T23:59:59+00:00
Accession:  0001104659-25-001350
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin reports Netherton Syndrome patient achieves near-clear skin after 12 weeks of QRX003 twice-daily
--------------------------------------------------------------------------------

- M-IASI score improved from 18 to 3; WINRS from 7 to 2; IGA from Moderate to Almost Clear after 12 weeks.
- Patient satisfaction scores further improved from 6-week to 12-week mark; no safety concerns observed.
- Data follows positive interim results announced Dec 2024; first subject completed full 12-week twice-daily dosing with QRX003.
- Quoin is developing QRX003 for Netherton Syndrome, a rare genetic skin disorder with no approved therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925001350/0001104659-25-001350-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925001350/tm252105d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-001350

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer